- Home
- IGI vs PROK Comparison
IGI vs PROK Comparison
Compare IGI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGI
- PROK
- Stock Information
- Founded
- IGI 2009
- PROK 2015
- Country
- IGI United States
- PROK United States
- Employees
- IGI N/A
- PROK N/A
- Industry
- IGI Investment Managers
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IGI Finance
- PROK Health Care
- Exchange
- IGI Nasdaq
- PROK Nasdaq
- Market Cap
- IGI 190.2M
- PROK 220.6M
- IPO Year
- IGI N/A
- PROK N/A
- Fundamental
- Price
- IGI $16.72
- PROK $2.03
- Analyst Decision
- IGI
- PROK Buy
- Analyst Count
- IGI 0
- PROK 5
- Target Price
- IGI N/A
- PROK $4.50
- AVG Volume (30 Days)
- IGI 33.9K
- PROK 392.4K
- Earning Date
- IGI 01-01-0001
- PROK 11-19-2024
- Dividend Yield
- IGI 4.79%
- PROK N/A
- EPS Growth
- IGI N/A
- PROK N/A
- EPS
- IGI N/A
- PROK N/A
- Revenue
- IGI N/A
- PROK N/A
- Revenue This Year
- IGI N/A
- PROK N/A
- Revenue Next Year
- IGI N/A
- PROK N/A
- P/E Ratio
- IGI N/A
- PROK N/A
- Revenue Growth
- IGI N/A
- PROK N/A
- 52 Week Low
- IGI $15.13
- PROK $1.12
- 52 Week High
- IGI $17.79
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- IGI 36.03
- PROK 64.25
- Support Level
- IGI $16.48
- PROK $1.49
- Resistance Level
- IGI $16.87
- PROK $1.83
- Average True Range (ATR)
- IGI 0.13
- PROK 0.12
- MACD
- IGI 0.02
- PROK 0.06
- Stochastic Oscillator
- IGI 44.64
- PROK 100.00
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.